CONFERENCE SERIES: Biological Therapeutic Products
Recorded at: PEGS: The Essential Protein Engineering Summit  

http://www.chidb.com/bioteam//images/button.jpg  

Digital Course: Essential Consideration for Development of Antibody-Based Therapeutics from Discovery to the Clinic

May 16, 2010


About this Product:
The biologics market continues to witness an impressive rate of growth, and the Antibody-Based Therapeutics (ABTs) market in particular has contributed remarkably to the expansion of this segment within the pharmaceutical industry.  ABTs exhibit exclusive specificity for the target antigen they recognize.  This unique characteristic discriminates ABTs from other therapeutic modalities such as small molecule drugs. Successful strategies for development of ABTs require integration of relevant knowledge with respect to target antigen properties, antibody design criteria such as affinity, isotype selection, pharmacokinetic (PK)-pharmacodynamic (PD) properties, biophysical characterization and antibody cross-reactivity across species from the early stages of antibody development.  This introductory course will evaluate critical considerations necessary for effective development of ABTs.

  • This introductory course will evaluate critical considerations necessary for effective development of ABTs
  • Integration of relevant knowledge with respect to target antigen properties, antibody design criteria such as affinity, isotype selection, pharmacokinetic (PK)-pharmacodynamic (PD) properties, biophysical characterization and antibody cross-reactivity across species from the early stages of antibody development
  • Key learnings will include: Considerations for target selection, screening and preclinical development; Affinity and biophysical characterization; Translational Considerations


Recorded at:
SIXTH ANNUAL PEGS SUMMIT, MAY 17-21, 2010, BOSTON, MA

About the Conference:
PEGS is the largest event on engineering of recombinant proteins and alternative scaffolds.
The 2010 event had over 1000 attendees, 9 cutting-edge programs, 68 exhibiting companies , 9 visionary Keynote presentations, and 100+ posters

Agenda At A Glance: 

Considerations for Target Selection, Screening and Preclinical Development
Gadi BornsteinGadi Bornstein, Ph.D., Principal Scientist, AstraZeneca R&D 

Biography: Dr. Bornstein has experience in research and development with an emphasis in development of biologics and monoclonal antibodies. Dr. Bornstein is a Principal Scientist at AstraZeneca, where he currently leads several antibody programs within the Preclinical oncology portfolio. Dr. Bornstein is author or co-author of more than 25 scientific publications, abstracts, and patents.

Affinity and Biophysical Characterization
Scott KlakampScott Klakamp, Ph.D., Research Fellow, Biophysical Chemistry and Bioinformatics, Takeda 

Biography: Dr. Scott Klakamp is a Research Fellow at Takeda San Francisco. He leads the Biophysical Chemistry and Research Informatics Groups and has extensive experience in research and development involving the biophysical and analytical characterization of biologics and monoclonal antibodies. Dr. Klakamp is one of the leading scientists in utilizing Biacore®, KinExA®, and FACS techniques to measure the binding kinetics and equilibrium constants of human monoclonal antibody/antigen complexes.

Translational Considerations

Mohammad TabriziMohammad Tabrizi, Ph.D., Vice President, Preclinical Development, AnaptysBio, Inc. 

Biography: Mohammad Tabrizi, Ph.D. is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies. He is currently the Vice President of Preclinical Development at Anaptysbio Inc., a privately held biotechnology company in San Diego CA, USA, the leader in Somatic HyperMutation (SHM) technology for development of therapeutic antibodies.


About this Product:

3 Presentations
Over 117 slides
155 minutes
Single Copy - $345.00
Site License - $1,380.00